Hepatitis B Virus Infection - Natural History and Clinical Consequences

New England Journal of Medicine

Volumn 350, Issue 11, 2004, Pages 1118-1129

  Ganem, Don ^a   Prince, Alfred M ^b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NEW YORK BLOOD CENTER   (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ALPHA INTERFERON; ANTIVIRUS AGENT; BIOLOGICAL MARKER; CLEVUDINE; EMTRICITABINE; ENTECAVIR; HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; HEPATITIS B(E) ANTIGEN; INTERFERON; LAMIVUDINE; TENOFOVIR; THYMIDINE; VIRUS DNA;

BLOOD; CLINICAL FEATURE; CLINICAL TRIAL; DEPRESSION; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE TRANSMISSION; DRUG EFFICACY; DRUG FEVER; EPIDEMIOLOGICAL DATA; GENETICS; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNE RESPONSE; ISOLATION AND PURIFICATION; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; LIVER TUMOR; MYALGIA; NEPHROTOXICITY; PATHOGENESIS; PHYSIOLOGY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REVIEW; THROMBOCYTOPENIA; VIREMIA; VIROLOGY; VIRUS CLASSIFICATION; VIRUS GENE; VIRUS REPLICATION;

ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; CARCINOMA, HEPATOCELLULAR; DNA, VIRAL; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INTERFERONS; LAMIVUDINE; LIVER NEOPLASMS; VIREMIA; VIRUS REPLICATION;

EID: 1542316127     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMra031087     Document Type: Review

References (81)

1. Krugman S, Giles JP, Hammond J. Infectious hepatitis: evidence for two distinctive clinical, epidemiological, and immunological types of infection. JAMA 1967;200: 365-73.
2. Prince AM, Fuji H, Gershon RK. Immunohistochemical studies on the etiology of anicteric hepatitis in Korea. Am J Hyg 1964; 79:365-81.
3. Chung WK, Moon SK, Gerson RK, Prince AM, Popper H. Anicteric hepatitis in Korea. II. Serial histologic studies. Arch Intern Med 1964;113:535-42.
4. Prince AM, Gershon RK. The etiology of chronic active hepatitis in Korea. Yale J Biol Med 1979;52:159-67.
5. Blumberg BS, Alter HJ, Visnich S. A "new" antigen in leukemiasera. JAMA 1965;191:541-6.
6. Prince AM. Relation of Australia and SH antigens. Lancet 1968;2:462-3.
7. Idem. An antigen detected in the blood during the incubation period of serum hepatitis. Proc Natl Acad Sci U S A 1968;60:814-21.
8. Prince AM, Hargrove RL, Szmuness W, Cherubin CE, Fontana VJ, Jeffries GH. Immunologic distinction between infectious and serum hepatitis. N Engl J Med 1970; 282:987-91.
9. Krugman S, Giles JP. Viral hepatitis: new light on an old disease. JAMA 1970;212: 1019-29.
10. Marion PL. Use of animal models to study hepatitis B viruses. Prog Med Virol 1988;35:43-75.
11. Korba BE, Gowans EJ, Wells FV, Tennant BC, Clarke R, Gerin JL. Systemic distribution of woodchuck hepatitis virus in the tissues of experimentally infected woodchucks. Virology 1988;165:172-81.
12. Halpern MS, England JM, Deery DT, Petcu DJ, Mason WS, Molnar-Kimber KL. Viral nucleic acid synthesis and antigen accumulation in pancreas and kidney of Peking ducks infected with duck hepatitis B virus. Proc Natl Acad Sci U S A 1983;80:4865-9.
13. Barker LF, MaynardJE, Purcell RH, et al. Hepatitis B virus infection in chimpanzees: titration of subtypes. J Infect Dis 1975;132: 451-8.
14. Dane DS, Cameron CH, Briggs M. Virus-like particles in the serum of patients with Australia-antigen-associated hepatitis. Lancet 1970;1:695-8.
15. Ganem D. Assembly of hepadnaviral virions and subviral particles. Curr Top Microbiol Immunol 1991;168:61-83.
16. Robinson WS, Lutwick LI. The virus of hepatitis, type B. N Engl J Med 1976;295: 1168-75.
17. Summers J, O'Connell A, Millman I. Genome of hepatitis B virus: restriction enzyme cleavage and structure of DNA extracted from Dane particles. Proc Natl Acad Sci U S A 1975;72:4597-601.
18. Kao J-H. Hepatitis B viral genotypes: clinical relevance and molecular characteristics. J Gastroenterol Hepatol 2002;17:643-50.
19. Ganem D, Schneider RJ. Hepadnaviridae: the viruses and their replication. In: Knipe DM, Howley PM, eds. Fields virology, 4th ed. Vol. 2. Philadelphia: Lippincott Williams & Wilkins, 2001:2923-69.
20. Klingmüller U, Schaller H. Hepadnavirus infection requires interaction between the viral pre-S domain and a specific hepatocellular receptor. J Virol 1993;67:7414-22.
21. Bruss V, Ganem D. The role of envelope proteins in hepatitis B virus assembly. Proc Natl Acad Sci USA 1991;88:1059-63.
22. Takahashi K, Machida A, Funatsu G, et al. Immunochemical structure of hepatitis B e antigen in the serum. J Immunol 1983; 130:2903-7.
23. Okamoto H, Yotsumoto S, Akahane Y, et al. Hepatitis B viruses with precore region defects prevail in persistently infected hosts along with seroconversion to the antibody against e antigen. J Virol 1990;64:1298-303.
24. Zoulim F, Saputelli J, Seeger C. Woodchuck hepatitis virus X protein is required for viral infection in vivo. J Virol 1994;68: 2026-30.
25. Summers J, Mason WS. Replication of the genome of a hepatitis B-like virus by reverse transcription of an RNA intermediate. Cell 1982;29:403-15.
26. Tuttleman JS, Pourcel C, Summers J. Formation of the pool of covalently closed circular viral DNA in hepadnavirus-infected cells. Cell 1986;47:451-60.
27. Will H, Reiser W, Weimer T, et al. Replication strategy of human hepatitis B virus. J Virol 1987;61:904-11.
28. Pollack JR, Ganem D. Site-specific RNA binding by a hepatitis B virus reverse transcriptase initiates two distinct reactions: RNA packaging and DNA synthesis. J Virol 1994; 68:5579-87.
29. Wang GH, Seeger C. Novel mechanism for reverse transcription in hepatitis B viruses. J Virol 1993;67:6507-12.
30. de Franchis R, Meucci G, Vecchi M, et al. The natural history of asymptomatic hepatitis B surface antigen carriers. Ann Intern Med 1993;118:191-4.
31. Stevens CE, Beasley RP, Tsui J, Lee W-C. Vertical transmission of hepatitis B antigen in Taiwan. N Engl J Med 1975;292:771-4.
32. Chisari FV, Ferrari C. Hepatitis B virus immunopathogenesis. Annu Rev Immunol 1995;13:29-60.
33. Chisari FV. Hepatitis B virus transgenic mice: models of viral immunobiology and pathogenesis. Curr Top Microbiol Immunol 1996;206:149-73.
34. Guidotti LG, Ishikawa T, Hobbs MV, Matzke B, Schreiber R, Chisari FV. Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. Immunity 1996; 4:25-36.
35. Baron JL, Gardiner L, Nishimura S, Shinkai K, Locksley R, Ganem D. Activation of a nonclassical NKT cell subset in a transgenic mouse model of hepatitis B virus infection. Immunity 2002;16:583-94.
36. Cavanaugh VJ, Guidotti LG, Chisari FV. Inhibition of hepatitis B virus replication during adenovirus and cytomegalovirus infections in transgenic mice. J Virol 1998;72: 2630-7.
37. Wright TL, Lau JY. Clinical aspects of hepatitis B virus infection. Lancet 1993;342: 1340-4.
38. Hoofnagle JH. Serologic markers of hepatitis B virus infection. Annu Rev Med 1981; 32:1-11.
39. Ribeiro RM, Lo A, Perelson AS. Dynamics of hepatitis B virus infection. Microbes Infect 2002;4:829-35.
40. Kajino K, Jilbert AR, Saputelli J, Aldrich CE, Cullen J, Mason WS. Woodchuck hepatitis virus infections: very rapid recovery after a prolonged viremia and infection of virtually every hepatocyte. J Virol 1994;68: 5792-803.
41. Koff RS, Slavin MM, Connelly JD, Rosen DR, Contagiousness of acute hepatitis B: secondary attack rates in household contacts. Gastroenterology 1977;72:297-300.
42. Prince AM, Lee D-H, Brotman B. Infectivity of blood from PCR-positive, HBsAgnegative, anti-HBs-positive cases of resolved hepatitis B infection. Transfusion 2001;41: 329-32.
43. Weinberger KM, Wiedenmann E, Bohm S, Jilg W. Sensitive and accurate quantitation of hepatitis B virus DNA using a kinetic fluorescence detection system (TaqMan PCR). J Virol Methods 2000;85:75-82.
44. Tedder RS, Ijaz S, Gilbert N, et al. Evidence for a dynamic host-parasite relationship in e-negative hepatitis B carriers. J Med Virol 2002;68:505-12.
45. Sung J, Chan HL-Y, Wong ML, et al. Relationship of clinical and virological factors with hepatitis activity in hepatitis B e antigen-negative chronic hepatitis B virus-infected patients. J Viral Hepat 2002;9:229-34.
46. Brunetto MR, Giarin MM, Oliveri F, et al. Wild-type and e antigen-minus hepatitis B viruses and course of chronic hepatitis. Proc Natl Acad Sci U S A 1991;88:4186-90.
47. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2001;34:1225-41.
48. Beasley RP. Hepatitis B virus: the major etiology of hepatocellular carcinoma. Cancer 1988;61:1942-56.
49. Yang H-I, Lu S-N, Liaw Y-F, et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 2002;347:168-74.
50. Fourel G, Trepo C, Bougueleret L, et al. Frequent activation of N-myc genes by hepadnavirus insertion in woodchuck liver tumours. Nature 1990;347:294-8.
51. Matsubara K, Tokino F. Integration of hepatitis B virus DNA and its implications for hepatocarcinogenesis. Mol Biol Med 1990;7:243-60.
52. Popper H, Roth L, Purcell RH, Tennant BC, Gerin JL. Hepatocarcinogenicity of the woodchuck hepatitis virus. Proc Natl Acad Sci U S A 1987;84:866-70.
53. Kim CM, Koike K, Saito I, Miyamura T, Jay G. HBx gene of hepatitis B virus induces liver cancer in transgenic mice. Nature 1991; 351:317-20.
54. Lauer U, Weiss L, Hofschneider PH, Kekule AS. The hepatitis B virus pre-S/S(t) transactivator is generated by 3′ truncations within a defined region of the S gene. J Virol 1992;66:5284-9.
55. Liaw YF, Tai DI, Chu CM, Chen TJ. Development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Hepatology 1988;8:493-6.
56. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003;348:800-7. [Erratum, N Engl J Med 2003; 348:1192.]
57. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003;348:800-7. [Erratum, N Engl J Med 2003; 348:1192.]
58. Niederau C, Heintges T, Lange S, et al. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 1996;334:1422-7.
59. Wong DK, Cheung A, O'Rourke K, et al. Effect of alpha-interferon in patients with hepatitis B e antigen-positive chronic hepatitis B: a meta-analysis. Ann Intern Med 1993; 119:312-23.
60. Ikeda K, Saitoh S, Suzuki Y, et al. Interferon decreases hepatocellular carcinogenesis in patients with cirrhosis caused by the hepatitis B virus: a pilot study. Cancer 1998; 82:827-35.
61. Puoti M, Airoldi M, Bruno R, et al. Hepatitis B virus co-infection in human immunodeficiency virus-infected subjects. AIDS Rev 2002;4:27-35.
62. Dienstag JL, Schiff ER, Wright TL, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999;341:1256-63.
63. Villeneuve JP, Condreay LD, Willems B, et al. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. Hepatology 2000;31:207-10.
64. Trepo C, Guillevin L. Polyarteritis nodosa and extrahepatic manifestations of HBV infection: the case against autoimmune intervention in pathogenesis. J Autoimmun 2001;16:269-74.
65. Chien RN, Liaw YF, Atkins M. Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Hepatology 1999; 30:770-4.
66. Melegari M, Scaglioni PP, Wands JR. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective. Hepatology 1998;27:628-33.
67. Liaw YF, Cheung NW, Chang TT, et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Gastroenterology 2000;119:172-80.
68. Honkoop P, de Man RA, Niesters HG, Zondervan PE, Schalm SW. Acute exacerbation of chronic hepatitis B virus infection after withdrawal of lamivudine therapy. Hepatology 2000;32:635-9.
69. Marcellin P, Chang T-T, Lim SG, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003;348:808-16.
70. Ying C, De Clercq E, Nicholson W, Furman P, Neyts L. Inhibition of the replication of the DNA polymerase M550V mutation variant of human hepatitis B virus by adefovir, tenofovir, L-FMAU, DAPD, penciclovir and lobucavir. J Viral Hepat 2000;7:161-5.
71. Petrillo R, Schiff E, Yoshida E, etal. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatology 2000;32:129-34.
72. Yang H, Westland CE, Delaney WE IV, et al. Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks. Hepatology 2002;36: 464-73.
73. Nelson M, Portsmouth J, Stebbing J, et al. An open-label study of tenofovir in HIV-1 and hepatitis B virus co-infected individuals. AIDS 2003;17:F7-F10.
74. Ristig MB, Crippin J, Aberg JA, et al. Tenofovir disoproxil fumarate therapy for chronic hepatitis B in human immunodeficiency virus/hepatitis B virus-coinfected individuals for whom interferon-alpha and lamivudine therapy have failed. J Infect Dis 2002;186:1844-7.
75. Lai C-L, Kosmawati M, Lao J, et al. Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection. Gastroenterology 2002; 123:1831-8.
76. Standring DN, Bridges EG, Placidi L, et al. Antiviral beta-L-nucleosides specific for hepatitis B virus infection. Antivir Chem Chemother 2001;12:Suppl 1:119-29.
77. Chin R, Shaw T, Torresi J, et al. In vitro susceptibilities of wild-type or drug-resistant hepatitis B virus to (-)-beta-D-2,6-diaminopurine dioxolane and 2′-fluoro-5-methylbeta-L-arabinofuranosyluracil. Antimicrob Agents Chemother 2001;45:2495-501.
78. Samuel D, Muller R, Alexander G, et al. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 1993;329:1842-7.
79. Terrault NA, Zhou S, Combs C, et al. Prophylaxis in liver transplant recipients using a fixed dosing schedule of hepatitis B immunoglobulin. Hepatology 1996;24:1327-33.
80. Perrillo R, Rakela J, Dienstag J, et al. Multicenter study of lamivudine therapy for hepatitis B after liver transplantation. Hepatology 1999;29:1581-6.
81. Anselmo DM, Ghobrial RM, Jung LC, et al. New era of liver transplantation for hepatitis B: 17-year single-center experience. Ann Surg 2002;235:611-20.